US Renal Data System. USRDS 1999 Annual Data Report. Bethesda, Md: National Institutes of Health, National Institute of
Diabetes, Digestive, and Kidney Diseases; 1999.
Klag MJ, Whelton PK, Randall BL.
et al. Blood pressure and end-stage renal disease in men. N Engl J Med.1996;334:13-18.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD.for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic
nephropathy. N Engl J Med.1993;329:1456-1462.
Maschio G, Alberti D, Janin G.
et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on
the progression of chronic renal insufficiency. N Engl J Med.1996;334:939-945.
Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on
progression of NIDDM associated nephropathy. Kidney Int.1996;50:1641-1650.
The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline
in glomerular filtration rate and risk of terminal renal failure in proteinuric,
non-diabetic nephropathy. Lancet.1997;349:1857-1863.
Perna A, Remuzzi G. Abnormal permeability to proteins and glomerular lesions: a meta-analysis
of experimental and human studies. Am J Kidney Dis.1996;27:34-41.
Rahman M, Douglas JG, Wright JT. Pathophysiology and treatment implications of hypertension in the African-American
population. Endocrinol Metab Clin North Am.1997;26:125-144.
Weir MR, Dworkin LD. Antihypertensive drugs, dietary salt, and renal protection: how low
should you go and with which therapy? Am J Kidney Dis.1998;32:1-22.
Koshy S, Bakris GL. Therapeutic approaches to achieve desired blood pressure goals: focus
on calcium channel blockers. Cardiovasc Drugs Ther.2000;14:295-301.
Dworkin LD, Feiner HD, Parker M, Tolbert E. Effects of nifedipine and enalapril on glomerular structure and function
in uninephrectomized SHR. Kidney Int.1991;39:1112-1117.
Dworkin LD, Benstein JA, Parker M, Tolbert E, Feiner HD. Calcium antagonists and converting enzyme inhibitors reduce renal injury
by different mechanisms. Kidney Int.1993;43:808-814.
Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R. Effect of calcium channel or beta-blockade on the progression of diabetic
nephropathy in African Americans. Hypertension.1997;29:744-750.
Ruggenenti P, Perna A, Benini R, Remuzzi G. Effects of dihydropyridine calcium channel blockers, angiotensin-converting
enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies.
Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J Am Soc Nephrol.1998;9:2096-2101.
Tarif N, Bakris GL. Preservation of renal function: the spectrum of effects by calcium-channel
blockers. Nephrol Dial Transplant.1997;12:2244-2250.
Guasch A, Parham M, Zayas CF, Campbell O, Nzerue C, Macon E. Contrasting effects of calcium channel blockade versus converting enzyme
inhibition on proteinuria in African Americans with non-insulin-dependent
diabetes mellitus and nephropathy. J Am Soc Nephrol.1997;8:793-798.
Wright Jr JT, Kusek JW, Toto RD.
et al. Design and baseline characteristics of participants in the African
American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials.1996;17(4 suppl):3S-16S.
Hall WD, Kusek JW, Kirk KA.
et al. Short-term effects of blood pressure control and antihypertensive drug
regimen on glomerular filtration rate: the African-American Study of Kidney
Disease and Hypertension Pilot Study. Am J Kidney Dis.1997;29:720-728.
Perloff D, Grim C, Flack J.
et al. Human blood pressure determination by sphygmomanometry. Circulation.1993;88(5 pt 1):2460-2470.
Coresh J, Toto RD, Kirk KA.
et al. Creatinine clearance as a measure of GFR in screenees for the African-American
Study of Kidney Disease and Hypertension pilot study. Am J Kidney Dis.1998;32:32-42.
De Cesaris R, Ranieri G, Filitti V, Andriani A, Bonfantino MV. Effects of atenolol and enalapril on kidney function in hypertensive
diabetic patients. J Cardiovasc Pharmacol.1993;22:208-214.
ter Wee PM, De Micheli AG, Epstein M. Effects of calcium antagonists on renal hemodynamics and progression
of nondiabetic chronic renal disease. Arch Intern Med.1994;154:1185-1202.
Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum
creatinine: is this a cause for concern? Arch Intern Med.2000;160:685-693.
Short-term effects of protein intake, blood pressure, and antihypertensive
therapy on glomerular filtration rate in the Modification of Diet in Renal
Disease Study. J Am Soc Nephrol.1996;7:2097-2109.
Ruggenenti P, Perna A, Gherardi G.
et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies
with non-nephrotic proteinuria. Lancet.1999;354:359-364.
O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics.1979;35:549-556.
Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination
(PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis.1999;33:1004-1010.
Kloke HJ, Branten AJ, Huysmans FT, Wetzels JF. Antihypertensive treatment of patients with proteinuric renal diseases:
risks or benefits of calcium channel blockers? Kidney Int.1998;53:1559-1573.
Jafar T, Schmid C, Landa M.
et al. The effect of angiotensin-converting-enzyme inhibitors on the progression
of non-diabetic renal disease: a pooled analysis of individual patient data
from 11 randomized controlled trials. Ann Intern Med.In press.
Anderson S. Renal hemodynamic effects of calcium antagonists in rats with reduced
renal mass. Hypertension.1991;17:288-295.
Griffin KA, Picken MM, Bakris GL, Bidani AK. Class differences in the effects of calcium channel blockers in the
rat remnant kidney model. Kidney Int.1999;55:1849-1860.
Kvam FI, Ofstad J, Iversen BM. Effects of antihypertensive drugs on autoregulation of RBF and glomerular
capillary pressure in SHR. Am J Physiol.1998;275(pt 2):F576-F584.
Mimran A, Insua A, Ribstein J, Bringer J, Monnier L. Comparative effect of captopril and nifedipine in normotensive patients
with incipient diabetic nephropathy. Diabetes Care.1988;11:850-853.
Demarie BK, Bakris GL. Effects of different calcium antagonists on proteinuria associated
with diabetes mellitus. Ann Intern Med.1990;113:987-988.
Little RJA, Rubin DB. Statistical Analysis With Missing Data. New York, NY: John Wiley & Sons Inc; 1987.
Schluchter M, Greene T, Beck G. Analysis of change in the presence of informative censoring: Application
to to longitudinal clinical trial of progressive renal disease. Stat Med.2001;20:989-1007.
Staessen JA, Fagard R, Thijs L.
et al. Randomised double-blind comparison of placebo and active treatment
for older patients with isolated systolic hypertension. Lancet.1997;350:757-764.
Wang JG, Liu G, Wang X.
et al. Long-term blood pressure control in older Chinese patients with isolated
systolic hypertension: a progress report on the Syst-China trial. J Hum Hypertens.1996;10:735-742.
Hansson L, Linholm LH, Niskanen L.
et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional
therapy on cardiovascular morbidity and mortality in hypertension: the Captopril
Prevention Project (CAPPP) randomized trial. Lancet.1999;353:611-616.
Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering
drugs: results of prospectively designed overviews of randomised trials. Blood
Pressure Lowering Treatment Trialists' Collaboration. Lancet.2000;356:1955-1964.